The trials did not select patients by ABC transporter expression, and clinical trials targeted ABCB1 and ABCG2 (with only a few targeting ABCC2), but other ABC transporters also likely to play important roles in ovarian cancer progression and chemotherapy resistance[7]. Here, ABCG2 is linked to ovarian carcinoma.